Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?

作者：Dubouloz Angele^*; Rouzaud Michel; Tsvang Lev; Verbakel Wilko; Bjorkqvist Mikko; Linthout Nadine; Lencart Joana; Perez Moreno Juan Maria; Ozen Zeynep; Escude Lluis; Zilli Thomas; Miralbell Raymond

来源：Radiation Oncology, 2018, 13(1): 114.

DOI：10.1186/s13014-018-1059-1

• Stereotactic body radiotherapy
• Endorectal balloon
• Dosimetric optimization
• Prostate cancer
• Urethra sparing

Background: This is a dosimetric comparative study intended to establish appropriate low-to-intermediate dose-constraints for the rectal wall (R-wall) in the context of a randomized phase-II trial on urethra-sparing stereotactic body radiotherapy (SBRT) for prostate cancer. The effect of plan optimization on low-to-intermediate R-wall dose and the potential benefit of an endorectal balloon (ERB) are investigated.
Methods: Ten prostate cancer patients, simulated with and without an ERB, were planned to receive 36.25Gy (7.25Gyx5) to the planning treatment volume (PTV) and 32.5Gy to the urethral planning risk volume (uPRV). Reference plans with and without the ERB, optimized with respect to PTV and uPRV coverage objectives and the organs at risk dose constraints, were further optimized using a standardized stepwise approach to push down dose constraints to the R-wall in the low to intermediate range in five sequential steps to obtain paired plans with and without ERB (Vm(1) to Vm(5)). Homogeneity index for the PTV and the uPRV, and the Dice similarity coefficient (DSC) for the PTV were analyzed. Dosimetric parameters for R-wall including the median dose and the dose received by 10 to 60% of the R-wall, bladder wall (B-wall) and femoral heads (F-Heads) were compared. The monitor units (MU) per plan were recorded.
Results: Vm(4) reduced by half D-30%, D-40%, D-50%, and D-med for R-wall and decreased by a third D-60% while HIPTV, HIuPRV and DSC remained stable with and without ERB compared to Vm(ref). HIPTV worsened at Vm(5) both with and without ERB. No statistical differences were observed between paired plans on R-wall, B-wall except a higher D-2% for F-heads with and without an ERB.
Conclusions: Further optimization to the R-wall in the context of urethra sparing prostate SBRT is feasible without compromising the dose homogeneity to the target. Independent of the use or not of an ERB, low-to-intermediate doses to the R-wall can be significantly reduced using a four-step sequential optimization approach.

• 出版日期2018-6-19